CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 128 enrolled
Drug / intervention
20 mg doxycycline hyclate +1 moredrug
Likely dose
20 mg doxycycline hyclatefrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00066027
NCT00066027Phase 3Completed
CompareCT.gov

Low-Dose Doxycycline Effects on Osteopenic Bone Loss

University of Nebraska·interventional·Posted Aug 5, 2003·Updated Sep 6, 2023

In Brief

A Phase 3 clinical trial evaluating 20 mg doxycycline hyclate and Placebo for Periodontitis. Completed, enrolled 128 participants across 2 sites.

Detailed Summary

The primary purpose of this clinical trial is to determine whether low-dose doxycycline can reduce alveolar bone density loss in postmenopausal osteopenic women with periodontitis and not on hormone replacement therapy (i.e., estrogen deficient).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPeriodontitis
CountriesUnited States
CollaboratorsNational Institute of Dental and Craniofacial Research (NIDCR)

Timeline

Phase 3CompletedFinished
20022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 5, 2003
Enrollment StartJun 1, 2002
Primary CompletionOct 1, 2005
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 22.9 years ago

Interventions

20 mg doxycycline hyclatedrug

Subjects in the LDD group took 20 mg doxycycline hyclate tablets twice daily for two years

Placebodrug

Subjects in the placebo group took a placebo look-alike twice daily for two years.